Your browser is no longer supported. Please, upgrade your browser.
Settings
ABIO ARCA biopharma, Inc. daily Stock Chart
ABIO [NASD]
ARCA biopharma, Inc.
Index- P/E- EPS (ttm)-3.08 Insider Own0.30% Shs Outstand9.30M Perf Week-3.36%
Market Cap24.18M Forward P/E- EPS next Y- Insider Trans100.31% Shs Float5.88M Perf Month-0.98%
Income-5.00M PEG- EPS next Q- Inst Own8.70% Short Float2.48% Perf Quarter-42.67%
Sales- P/S- EPS this Y59.80% Inst Trans0.97% Short Ratio0.16 Perf Half Y4.68%
Book/sh5.74 P/B0.70 EPS next Y- ROA-53.30% Target Price- Perf Year-23.96%
Cash/sh1.83 P/C2.20 EPS next 5Y- ROE-60.60% 52W Range2.21 - 22.00 Perf YTD-29.43%
Dividend- P/FCF- EPS past 5Y41.30% ROI- 52W High-81.68% Beta2.98
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin- 52W Low82.35% ATR0.26
Employees9 Current Ratio8.70 Sales Q/Q- Oper. Margin- RSI (14)38.25 Volatility3.83% 5.95%
OptionableNo Debt/Eq0.00 EPS Q/Q36.10% Profit Margin- Rel Volume0.17 Prev Close4.10
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume901.09K Price4.03
Recom- SMA20-8.15% SMA50-16.39% SMA200-22.56% Volume151,751 Change-1.71%
Feb-27-18Initiated Ascendiant Capital Markets Buy $2
Oct-09-13Initiated Dawson James Buy $3.75
Oct-07-20 08:30AM  
Oct-05-20 04:30PM  
Sep-21-20 08:00AM  
Aug-17-20 08:49AM  
Aug-12-20 08:00AM  
Aug-05-20 04:15PM  
Jul-07-20 08:30AM  
Jun-03-20 09:56AM  
09:56AM  
Jun-01-20 08:20AM  
May-29-20 12:24PM  
09:59AM  
May-28-20 04:19PM  
12:14PM  
10:27AM  
08:00AM  
May-07-20 08:30AM  
May-06-20 04:30PM  
Feb-18-20 04:30PM  
Feb-01-20 08:31AM  
Nov-06-19 04:10PM  
Nov-03-19 08:47AM  
Sep-12-19 08:30AM  
Sep-11-19 08:30AM  
Sep-04-19 01:37PM  
Aug-21-19 09:49AM  
Aug-01-19 04:30PM  
Jun-04-19 07:09AM  
May-13-19 09:00AM  
May-08-19 04:30PM  
May-01-19 08:30AM  
Apr-23-19 08:30AM  
Mar-18-19 08:30AM  
Mar-06-19 08:00AM  
Feb-27-19 04:15PM  
Feb-20-19 07:30AM  
Jan-16-19 08:30AM  
Dec-26-18 11:47AM  
Dec-20-18 04:01PM  
Nov-14-18 04:30PM  
Nov-12-18 08:30AM  
Nov-05-18 08:30AM  
Oct-10-18 04:16PM  
Oct-02-18 08:00AM  
Sep-18-18 08:30AM  
Aug-09-18 04:15PM  
Aug-03-18 09:45AM  
Jul-31-18 12:15PM  
08:30AM  
08:10AM  
Jun-19-18 07:05AM  
May-29-18 08:30AM  
May-11-18 08:20AM  
May-10-18 08:30AM  
07:15AM  
May-08-18 04:15PM  
Apr-23-18 08:30AM  
Apr-03-18 07:20AM  
Mar-22-18 04:30PM  
Feb-27-18 03:00PM  
Feb-26-18 02:18PM  
08:00AM  
Jan-23-18 05:13PM  
Jan-08-18 08:30AM  
Jan-02-18 05:09PM  
Dec-08-17 06:13PM  
Nov-30-17 02:25PM  
Nov-20-17 08:05AM  
Nov-17-17 08:10AM  
Nov-16-17 08:30AM  
Nov-09-17 04:05PM  
Oct-23-17 08:16PM  
Sep-21-17 08:30AM  
Aug-16-17 08:30AM  
Aug-09-17 04:30PM  
Aug-03-17 04:15PM  
Jun-20-17 08:30AM  
May-15-17 08:30AM  
Apr-26-17 08:30AM  
Apr-18-17 08:30AM  
Mar-25-17 01:04PM  
Mar-21-17 04:46PM  
04:30PM  
04:10PM  
Mar-06-17 04:32PM  
08:30AM  
Mar-01-17 04:47PM  
Feb-21-17 08:46AM  
08:30AM  
Jan-18-17 04:32PM  
08:30AM  
Jan-11-17 04:54PM  
Jan-04-17 08:30AM  
Dec-20-16 02:26PM  
Nov-15-16 08:30AM  
Nov-14-16 05:19PM  
05:08PM  
04:15PM  
Oct-06-16 04:07PM  
08:30AM  
ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CONWAY ROBERT EChairman of the BoardSep 25Buy4.285,00021,40020,000Sep 25 04:20 PM
CONWAY ROBERT EChairman of the BoardSep 22Buy4.663,05614,24115,000Sep 24 04:20 PM
CONWAY ROBERT EChairman of the BoardSep 21Buy4.7710,00047,66011,944Sep 21 05:00 PM
ACTG Acacia Research Corporation daily Stock Chart
ACTG [NASD]
Acacia Research Corporation
Index- P/E- EPS (ttm)-0.29 Insider Own1.40% Shs Outstand48.46M Perf Week2.76%
Market Cap165.59M Forward P/E83.75 EPS next Y0.04 Insider Trans3.05% Shs Float46.40M Perf Month-0.89%
Income-14.40M PEG- EPS next Q-0.02 Inst Own67.50% Short Float2.65% Perf Quarter-17.08%
Sales8.30M P/S19.95 EPS this Y83.30% Inst Trans0.89% Short Ratio6.21 Perf Half Y25.00%
Book/sh3.36 P/B1.00 EPS next Y126.70% ROA-5.70% Target Price- Perf Year30.86%
Cash/sh3.72 P/C0.90 EPS next 5Y20.00% ROE-8.60% 52W Range1.75 - 4.46 Perf YTD25.94%
Dividend- P/FCF- EPS past 5Y23.90% ROI-17.20% 52W High-24.89% Beta0.76
Dividend %- Quick Ratio2.90 Sales past 5Y-38.80% Gross Margin75.50% 52W Low91.43% ATR0.15
Employees17 Current Ratio2.90 Sales Q/Q-61.80% Oper. Margin- RSI (14)43.75 Volatility4.66% 3.74%
OptionableYes Debt/Eq0.70 EPS Q/Q174.00% Profit Margin- Rel Volume0.31 Prev Close3.36
ShortableYes LT Debt/Eq0.00 EarningsAug 10 BMO Payout- Avg Volume198.18K Price3.35
Recom- SMA20-0.13% SMA50-7.83% SMA2007.55% Volume61,203 Change-0.30%
May-22-20Initiated Craig Hallum Buy $4
Jul-29-16Reiterated Barclays Underweight $4 → $6
May-23-16Upgrade Northland Capital Market Perform → Outperform
Dec-23-15Reiterated Lake Street Buy $12 → $6.50
Aug-20-15Reiterated Barclays Equal Weight $15 → $12
Feb-20-15Reiterated Cowen Outperform $24 → $20
Jan-21-15Reiterated Northland Capital Outperform $23 → $17
Sep-18-14Initiated Northland Capital Outperform $23
Jul-29-14Reiterated Barclays Equal Weight $15 → $19
Feb-21-14Reiterated Barclays Equal Weight $19 → $15
Nov-04-13Reiterated Cowen Outperform $36 → $24
Sep-17-13Initiated Standpoint Research Buy $33
Jul-23-13Reiterated Barclays Equal Weight $28 → $23
Feb-22-13Reiterated Barclays Equal Weight $28 → $33
Apr-20-12Reiterated Barclays Equal Weight $45 → $47
Jul-08-11Initiated Barclays Capital Equal Weight $41
Apr-19-11Initiated GARP Research Buy
Jul-25-08Downgrade Davenport Strong Buy → Buy $8
Apr-27-07Reiterated Davenport Strong Buy $20 → $24
Oct-25-20 08:13AM  
Sep-10-20 06:03AM  
Sep-01-20 06:34AM  
Aug-10-20 08:00AM  
Jul-29-20 04:30PM  
Jul-03-20 06:27PM  
09:12AM  
Jun-05-20 08:09AM  
07:00AM  
06:00AM  
03:51AM  
May-11-20 08:00AM  
May-05-20 09:10AM  
Apr-21-20 06:00AM  
Mar-16-20 01:05PM  
Mar-14-20 08:39AM  
Mar-12-20 09:00AM  
08:00AM  
Feb-25-20 04:00PM  
Feb-06-20 10:19AM  
Dec-16-19 02:15PM  
Dec-13-19 04:05PM  
Dec-02-19 08:40PM  
Nov-18-19 09:03AM  
Nov-12-19 08:00AM  
Oct-31-19 06:00AM  
Oct-07-19 07:29AM  
Sep-13-19 07:48PM  
Sep-11-19 01:39PM  
Sep-09-19 05:06PM  
Aug-07-19 01:07PM  
Aug-05-19 06:43PM  
Jul-29-19 01:46PM  
Jun-26-19 06:27PM  
May-20-19 12:28AM  
May-10-19 09:00AM  
May-09-19 04:28PM  
04:00PM  
03:15PM  
May-03-19 01:22PM  
Apr-22-19 02:21PM  
Mar-27-19 12:25PM  
Mar-15-19 05:48PM  
03:31PM  
Mar-13-19 04:25PM  
04:00PM  
Feb-27-19 09:00AM  
Jan-29-19 01:59PM  
Jan-23-19 02:05PM  
Dec-12-18 09:06AM  
Nov-16-18 07:30AM  
Oct-29-18 11:53PM  
Oct-25-18 05:38PM  
04:00PM  
Oct-05-18 08:00AM  
Sep-18-18 12:21PM  
Aug-24-18 07:55AM  
Aug-10-18 05:30PM  
Aug-08-18 05:30PM  
04:27PM  
04:00PM  
02:30PM  
Aug-01-18 03:15PM  
Jul-31-18 06:11PM  
Jun-20-18 08:25AM  
Jun-14-18 11:16AM  
Jun-07-18 09:00AM  
Jun-04-18 10:25AM  
10:11AM  
May-31-18 01:45PM  
01:05PM  
May-30-18 03:03PM  
09:43AM  
07:40AM  
May-29-18 10:15AM  
May-25-18 09:22AM  
May-24-18 04:30PM  
May-21-18 08:00AM  
May-15-18 10:34AM  
May-14-18 08:00AM  
May-04-18 12:02PM  
May-03-18 09:35PM  
May-02-18 05:03AM  
May-01-18 04:00PM  
Apr-27-18 07:50AM  
Apr-18-18 06:00AM  
Apr-10-18 03:21PM  
Apr-03-18 10:04AM  
Apr-02-18 04:15PM  
Mar-21-18 02:55PM  
06:01AM  
Mar-20-18 10:14AM  
Feb-21-18 08:00AM  
Feb-16-18 02:55PM  
Feb-15-18 08:00AM  
08:00AM  
Feb-14-18 09:36AM  
08:00AM  
08:00AM  
Feb-13-18 04:00PM  
Acacia Research Corporation, together with its subsidiaries, invests in intellectual property and related absolute return assets; and engages in the licensing and enforcement of patented technologies. It assists patent owners with the prosecution and development of their patent portfolios; protection of their patented inventions from unauthorized use; generation of licensing revenue from users of their patented technologies; and enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation. The company owns or controls the rights to various patent portfolios, which include U.S. patents and foreign counterparts covering technologies used in a range of industries. It has executed approximately 1,570 license agreements, and approximately 200 patent portfolio licensing and enforcement programs. Acacia Research Corporation was founded in 1993 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OCONNELL MAUREENDirectorSep 08Buy3.7713,47050,845138,914Sep 08 08:18 PM
OCONNELL MAUREENDirectorSep 04Buy3.7811,53043,631125,444Sep 08 08:18 PM
Booth Marc W.Chief IP OfficerMay 08Sale2.404,48910,779106,141May 11 12:38 PM
Booth Marc W.Chief IP OfficerNov 08Sale2.594,37011,302110,630Nov 12 12:41 PM
ADMA ADMA Biologics, Inc. daily Stock Chart
ADMA [NASD]
ADMA Biologics, Inc.
Index- P/E- EPS (ttm)-0.87 Insider Own0.70% Shs Outstand86.35M Perf Week-0.88%
Market Cap197.71M Forward P/E- EPS next Y-0.52 Insider Trans8.79% Shs Float62.71M Perf Month10.29%
Income-61.40M PEG- EPS next Q-0.20 Inst Own62.00% Short Float22.18% Perf Quarter-21.88%
Sales37.20M P/S5.31 EPS this Y38.90% Inst Trans-1.01% Short Ratio2.21 Perf Half Y-29.25%
Book/sh0.89 P/B2.53 EPS next Y40.20% ROA-36.80% Target Price- Perf Year-51.92%
Cash/sh0.86 P/C2.61 EPS next 5Y- ROE-104.30% 52W Range1.45 - 5.25 Perf YTD-43.75%
Dividend- P/FCF- EPS past 5Y13.30% ROI- 52W High-57.14% Beta1.97
Dividend %- Quick Ratio6.80 Sales past 5Y37.80% Gross Margin-34.10% 52W Low55.17% ATR0.15
Employees313 Current Ratio11.10 Sales Q/Q18.20% Oper. Margin- RSI (14)43.43 Volatility4.93% 7.38%
OptionableYes Debt/Eq1.26 EPS Q/Q7.70% Profit Margin- Rel Volume0.24 Prev Close2.29
ShortableYes LT Debt/Eq1.26 EarningsAug 05 AMC Payout- Avg Volume6.29M Price2.25
Recom1.70 SMA20-3.72% SMA50-8.07% SMA200-23.69% Volume1,514,620 Change-1.75%
Jun-04-19Initiated Jefferies Buy $8
Apr-15-19Reiterated H.C. Wainwright Buy $10 → $13
Feb-07-19Resumed H.C. Wainwright Buy $10
Dec-11-17Reiterated Maxim Group Buy $13 → $8
Nov-14-17Upgrade Raymond James Mkt Perform → Outperform
Jan-23-17Upgrade Maxim Group Hold → Buy $13
Aug-01-16Downgrade Maxim Group Buy → Hold
Jul-25-16Reiterated Maxim Group Buy $24 → $14
May-13-15Reiterated Maxim Group Buy $18 → $24
Dec-08-14Initiated Oppenheimer Outperform $20
Dec-01-14Reiterated Maxim Group Buy $16 → $18
Oct-21-20 07:00AM  
Oct-14-20 08:43AM  
06:01AM  
Oct-07-20 09:16AM  
Oct-06-20 10:29AM  
Oct-01-20 08:41AM  
Sep-14-20 11:56AM  
Sep-09-20 07:00AM  
Sep-08-20 06:41AM  
Sep-03-20 07:00AM  
Sep-02-20 07:00AM  
Aug-25-20 08:55AM  
06:37AM  
Aug-24-20 01:30PM  
12:37PM  
11:10AM  
08:42AM  
Aug-10-20 01:03PM  
Aug-05-20 07:25PM  
04:05PM  
07:35AM  
Aug-03-20 07:34AM  
Jul-29-20 07:00AM  
Jul-07-20 08:55AM  
Jul-06-20 07:00AM  
Jul-03-20 10:13AM  
Jun-23-20 12:49PM  
07:00AM  
Jun-09-20 03:21PM  
Jun-01-20 09:44AM  
May-27-20 07:00AM  
May-21-20 07:00AM  
May-07-20 10:30AM  
08:42AM  
07:35AM  
May-06-20 08:15PM  
04:05PM  
May-01-20 06:13AM  
Apr-29-20 07:00AM  
Apr-03-20 03:48AM  
Mar-17-20 06:12AM  
Mar-12-20 04:05PM  
02:30PM  
Mar-05-20 06:59AM  
Mar-03-20 07:00AM  
Feb-24-20 07:00AM  
Feb-13-20 05:07AM  
Feb-11-20 04:20PM  
Feb-07-20 07:32AM  
Feb-06-20 08:41PM  
04:06PM  
05:53AM  
Jan-09-20 07:00AM  
Jan-07-20 07:00AM  
Dec-23-19 05:36AM  
Dec-17-19 07:08AM  
Dec-14-19 08:04PM  
Nov-13-19 07:08AM  
Nov-08-19 05:33AM  
Nov-06-19 05:02PM  
Nov-04-19 07:08AM  
Oct-28-19 03:05PM  
Oct-22-19 07:48AM  
Oct-21-19 07:48AM  
Oct-17-19 07:29AM  
Oct-09-19 11:08AM  
Oct-07-19 07:08AM  
Oct-03-19 07:08AM  
Sep-23-19 07:08AM  
Sep-09-19 02:54PM  
Aug-22-19 07:48AM  
Aug-08-19 07:51AM  
07:08AM  
Jul-08-19 08:22AM  
Jun-27-19 09:30AM  
09:28AM  
Jun-18-19 04:35PM  
Jun-06-19 07:25AM  
May-30-19 06:14PM  
May-29-19 07:11AM  
May-24-19 10:30AM  
May-21-19 04:20PM  
09:15AM  
May-16-19 08:00AM  
May-15-19 04:35PM  
May-10-19 06:58AM  
May-08-19 07:03PM  
04:18PM  
Apr-17-19 07:08AM  
Apr-03-19 08:19AM  
Apr-02-19 06:58PM  
10:26AM  
09:00AM  
07:30AM  
Apr-01-19 08:09PM  
Mar-13-19 08:19PM  
05:05PM  
Feb-25-19 07:38AM  
Feb-12-19 12:30PM  
07:38AM  
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DEMSKI MARTHA JDirectorSep 11Buy2.292,2005,0384,200Sep 14 08:00 AM
Grossman Jerrold BDirectorSep 10Buy2.225,00011,100160,864Sep 11 08:00 AM
Mond JamesEVP, CSO and CMOSep 08Buy2.204,0008,80073,174Sep 10 08:01 AM
Grossman Adam SPresident and CEOSep 08Buy2.244,0008,960176,098Sep 10 08:00 AM
Grossman Jerrold BDirectorAug 21Buy2.565,30013,586155,864Aug 25 08:00 AM
DEMSKI MARTHA JDirectorAug 13Buy2.882,0005,7602,000Aug 14 08:00 AM
Grossman Jerrold BDirectorAug 12Buy2.8910,20029,499150,564Aug 13 08:01 AM
LENZ BRIANEVP, CFOAug 11Buy2.974,00011,86076,142Aug 12 08:02 AM
Grossman Adam SPresident and CEOAug 11Buy2.971,0002,970172,098Aug 12 08:02 AM
Grossman Adam SPresident and CEOAug 10Buy3.065,00015,290171,098Aug 12 08:02 AM
Mond JamesEVP, CSO and CMOAug 10Buy2.887,00020,15069,174Aug 12 08:01 AM
PERCEPTIVE ADVISORS LLC10% OwnerMar 19Buy2.10500,0001,050,00016,584,802Mar 23 08:30 AM
PERCEPTIVE ADVISORS LLC10% OwnerFeb 11Buy3.504,563,70015,972,95016,084,802Feb 11 08:02 AM
Guiheen Lawrence P.DirectorFeb 11Buy3.5020,00070,00070,000Feb 11 10:18 AM
Mond JamesCSO and CMOFeb 11Buy3.504,28514,99822,174Feb 11 10:16 AM
Grossman Jerrold BDirectorFeb 11Buy3.5022,85780,00022,857Feb 11 10:15 AM
Grossman Jerrold BDirectorFeb 11Buy3.5022,85780,000132,864Feb 11 10:15 AM
LENZ BRIANEVP, CFOFeb 11Buy3.507,14224,99732,142Feb 11 10:13 AM
Grossman Adam SPresident and CEOFeb 11Buy3.5057,143200,001878,444Feb 11 10:11 AM
Grossman Adam SPresident and CEOFeb 11Buy3.5028,57199,99966,098Feb 11 10:11 AM
AHT Ashford Hospitality Trust, Inc. daily Stock Chart
AHT [NYSE]
Ashford Hospitality Trust, Inc.
Index- P/E- EPS (ttm)-38.36 Insider Own0.20% Shs Outstand10.31M Perf Week30.37%
Market Cap22.30M Forward P/E- EPS next Y-22.40 Insider Trans276.24% Shs Float8.52M Perf Month23.08%
Income-390.60M PEG- EPS next Q-15.30 Inst Own30.90% Short Float29.73% Perf Quarter-57.28%
Sales1.05B P/S0.02 EPS this Y10.00% Inst Trans-0.89% Short Ratio2.19 Perf Half Y-75.67%
Book/sh-3.78 P/B- EPS next Y43.70% ROA-8.50% Target Price- Perf Year-93.96%
Cash/sh13.06 P/C0.13 EPS next 5Y5.00% ROE-212.40% 52W Range1.31 - 30.80 Perf YTD-93.69%
Dividend- P/FCF- EPS past 5Y-14.80% ROI2.50% 52W High-94.29% Beta1.61
Dividend %- Quick Ratio- Sales past 5Y13.60% Gross Margin22.00% 52W Low34.35% ATR0.24
Employees116 Current Ratio- Sales Q/Q-89.60% Oper. Margin-15.40% RSI (14)51.91 Volatility17.68% 15.22%
OptionableYes Debt/Eq- EPS Q/Q-663.80% Profit Margin-37.10% Rel Volume1.61 Prev Close1.71
ShortableNo LT Debt/Eq- EarningsJul 30 AMC Payout- Avg Volume1.16M Price1.76
Recom2.80 SMA2012.86% SMA50-20.63% SMA200-81.55% Volume1,859,709 Change2.92%
Jun-17-20Upgrade DA Davidson Underperform → Neutral
Apr-06-20Downgrade B. Riley FBR Buy → Neutral $2 → $1.50
Mar-10-20Downgrade DA Davidson Neutral → Underperform
Jun-17-19Downgrade DA Davidson Buy → Neutral $7 → $4
Feb-27-17Upgrade FBR & Co. Mkt Perform → Outperform $8
Jan-11-17Downgrade Robert W. Baird Outperform → Neutral $7 → $8
Jan-04-17Downgrade FBR & Co. Outperform → Mkt Perform
Jul-21-16Downgrade Credit Suisse Outperform → Neutral
Feb-29-16Reiterated FBR Capital Outperform $9.50 → $8
Feb-29-16Reiterated Deutsche Bank Buy $9 → $10
Feb-01-16Downgrade Canaccord Genuity Buy → Hold
Jan-11-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Nov-20-15Initiated FBR Capital Outperform $9.50
Aug-12-15Downgrade BofA/Merrill Buy → Underperform
Jul-14-15Initiated Canaccord Genuity Buy $12
Jul-13-15Initiated Brean Capital Buy $14
Jun-02-15Reiterated UBS Neutral $11 → $9
May-12-14Upgrade R. F. Lafferty Neutral → Buy $12.40 → $14.60
Mar-03-14Downgrade R. F. Lafferty Buy → Neutral $10.80 → $12.40
Feb-19-14Upgrade Robert W. Baird Neutral → Outperform $14 → $12
Oct-22-20 09:44AM  
Oct-07-20 02:29PM  
Oct-06-20 09:36PM  
Oct-05-20 01:52PM  
Oct-02-20 05:40PM  
08:49AM  
Oct-01-20 04:15PM  
Sep-30-20 08:00AM  
Sep-28-20 08:50AM  
Sep-25-20 08:00AM  
Sep-23-20 09:13AM  
Sep-21-20 08:00AM  
06:03AM  
Sep-17-20 04:01PM  
Sep-10-20 08:50AM  
08:47AM  
Sep-01-20 06:01AM  
Aug-04-20 04:30PM  
02:36AM  
Jul-31-20 10:01AM  
Jul-29-20 08:45PM  
Jul-27-20 06:04AM  
Jul-17-20 03:32PM  
Jun-28-20 06:37PM  
Jun-18-20 09:00AM  
Jun-15-20 08:07PM  
08:19AM  
May-26-20 06:49AM  
May-23-20 08:26AM  
May-21-20 09:30PM  
04:30PM  
09:00AM  
May-19-20 04:58PM  
May-03-20 06:40AM  
May-02-20 11:15PM  
08:22PM  
07:00PM  
May-01-20 01:45PM  
Apr-30-20 05:00PM  
Apr-28-20 06:43AM  
Apr-26-20 04:30PM  
Apr-25-20 11:28AM  
08:00AM  
Apr-14-20 05:28PM  
09:54AM  
Mar-23-20 12:32PM  
Mar-15-20 08:44AM  
Mar-11-20 09:20PM  
Feb-25-20 07:35PM  
Feb-24-20 04:15PM  
Feb-05-20 06:37AM  
Jan-24-20 04:45PM  
Jan-02-20 04:15PM  
Dec-14-19 07:47PM  
Dec-10-19 09:31AM  
09:22AM  
Dec-06-19 09:50AM  
Dec-05-19 04:15PM  
Dec-04-19 08:00AM  
Nov-07-19 03:07PM  
Nov-05-19 07:50AM  
Oct-29-19 06:05PM  
04:15PM  
Oct-24-19 04:15PM  
Oct-22-19 06:14AM  
Oct-21-19 04:15PM  
Oct-15-19 08:00AM  
Oct-07-19 09:00AM  
Oct-03-19 07:30AM  
07:30AM  
Oct-02-19 06:15PM  
06:15PM  
08:00AM  
Sep-26-19 08:00AM  
Sep-25-19 08:30AM  
Sep-22-19 08:00AM  
Sep-12-19 08:00AM  
Sep-03-19 08:59AM  
Aug-19-19 01:40PM  
Aug-15-19 08:00AM  
Aug-07-19 12:30AM  
Aug-05-19 09:03AM  
08:00AM  
Aug-01-19 08:45PM  
04:15PM  
04:15PM  
01:07PM  
Jun-24-19 04:15PM  
Jun-21-19 08:25AM  
Jun-17-19 08:53AM  
Jun-14-19 04:35PM  
12:58PM  
08:00AM  
Jun-03-19 10:07AM  
08:00AM  
08:00AM  
May-22-19 11:55AM  
May-15-19 05:15PM  
May-09-19 09:30AM  
08:40AM  
Ashford Hospitality Trust is a real estate investment trust (REIT) focused on investing predominantly in upper upscale, full-service hotels.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ansell Benjamin J MDDirectorSep 10Buy5.0410,00050,40010,000Sep 14 04:16 PM
Ansell Benjamin J MDDirectorAug 28Buy2.9250,000146,000101,477Aug 31 07:15 PM
Ansell Benjamin J MDDirectorAug 07Buy3.8510,00038,50051,477Aug 10 09:36 PM
Ansell Benjamin J MDDirectorMar 19Buy0.5050,00025,000178,200Mar 20 04:58 PM
AIM AIM ImmunoTech Inc. daily Stock Chart
AIM [AMEX]
AIM ImmunoTech Inc.
Index- P/E- EPS (ttm)-1.49 Insider Own0.50% Shs Outstand39.69M Perf Week-7.49%
Market Cap82.59M Forward P/E- EPS next Y-0.37 Insider Trans13.28% Shs Float39.25M Perf Month3.45%
Income-11.30M PEG- EPS next Q-0.08 Inst Own4.70% Short Float4.57% Perf Quarter-34.78%
Sales0.20M P/S412.96 EPS this Y73.20% Inst Trans- Short Ratio0.51 Perf Half Y10.53%
Book/sh1.54 P/B1.36 EPS next Y17.80% ROA-33.40% Target Price- Perf Year271.68%
Cash/sh0.89 P/C2.36 EPS next 5Y25.00% ROE-42.70% 52W Range0.38 - 7.11 Perf YTD286.03%
Dividend- P/FCF- EPS past 5Y44.30% ROI-63.20% 52W High-70.46% Beta-0.85
Dividend %- Quick Ratio42.20 Sales past 5Y-6.60% Gross Margin- 52W Low451.18% ATR0.16
Employees31 Current Ratio42.20 Sales Q/Q37.90% Oper. Margin- RSI (14)45.21 Volatility5.10% 6.03%
OptionableNo Debt/Eq0.05 EPS Q/Q89.50% Profit Margin- Rel Volume0.19 Prev Close2.08
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume3.49M Price2.10
Recom2.00 SMA20-5.62% SMA50-4.12% SMA200-5.26% Volume672,900 Change0.96%
Oct-22-20 07:30AM  
Oct-06-20 09:00AM  
Sep-22-20 06:50AM  
Sep-16-20 06:50AM  
Sep-10-20 06:50AM  
Sep-08-20 06:50AM  
Aug-31-20 05:00PM  
Aug-27-20 09:15AM  
Aug-25-20 06:55AM  
Aug-21-20 11:18AM  
Aug-17-20 09:18AM  
06:55AM  
Aug-05-20 09:00AM  
Aug-03-20 08:00AM  
Jul-27-20 06:55AM  
Jul-09-20 06:30AM  
Jul-06-20 09:00AM  
Jun-29-20 06:55AM  
Jun-15-20 08:00AM  
Jun-11-20 09:05AM  
May-14-20 06:50AM  
Apr-29-20 06:30AM  
Apr-20-20 06:30AM  
Apr-06-20 06:30PM  
01:00PM  
06:30AM  
Mar-31-20 06:45AM  
Mar-26-20 08:00AM  
Mar-09-20 06:30AM  
Mar-08-20 11:34AM  
Feb-27-20 06:30AM  
Feb-18-20 06:30AM  
Feb-12-20 06:30AM  
Feb-11-20 06:30AM  
06:30AM  
Feb-05-20 06:30AM  
Jan-16-20 05:27AM  
Dec-11-19 12:20PM  
06:30AM  
Dec-04-19 06:30AM  
Nov-15-19 10:25AM  
06:30AM  
Oct-23-19 06:30AM  
Oct-07-19 06:30AM  
Sep-25-19 09:50AM  
Sep-24-19 06:30AM  
06:00AM  
Sep-19-19 08:43AM  
06:50AM  
Sep-16-19 06:50AM  
Sep-13-19 06:50AM  
Sep-10-19 07:30AM  
Sep-09-19 07:45AM  
Sep-06-19 06:30AM  
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EQUELS THOMAS K.CEO & PresidentSep 03Buy2.0312,31625,001184,033Sep 03 10:53 AM
EQUELS THOMAS K.CEOAug 21Buy2.3310,73025,001171,717Aug 21 08:08 AM
ANIX Anixa Biosciences, Inc. daily Stock Chart
ANIX [NASD]
Anixa Biosciences, Inc.
Index- P/E- EPS (ttm)-0.46 Insider Own5.40% Shs Outstand23.17M Perf Week-14.39%
Market Cap56.91M Forward P/E- EPS next Y-0.51 Insider Trans11.81% Shs Float22.37M Perf Month-1.74%
Income-9.90M PEG- EPS next Q-0.11 Inst Own7.10% Short Float6.82% Perf Quarter-22.07%
Sales0.00M P/S- EPS this Y25.90% Inst Trans4.93% Short Ratio5.78 Perf Half Y12.44%
Book/sh0.37 P/B6.11 EPS next Y-8.50% ROA-142.50% Target Price- Perf Year-42.20%
Cash/sh0.36 P/C6.32 EPS next 5Y- ROE-160.80% 52W Range1.33 - 4.24 Perf YTD-31.10%
Dividend- P/FCF- EPS past 5Y11.80% ROI-228.70% 52W High-46.70% Beta1.45
Dividend %- Quick Ratio7.60 Sales past 5Y-41.60% Gross Margin- 52W Low69.92% ATR0.21
Employees7 Current Ratio7.60 Sales Q/Q- Oper. Margin- RSI (14)42.57 Volatility9.58% 8.20%
OptionableNo Debt/Eq0.00 EPS Q/Q-3.90% Profit Margin- Rel Volume0.63 Prev Close2.39
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume264.18K Price2.26
Recom2.00 SMA20-12.40% SMA50-4.87% SMA200-10.26% Volume167,396 Change-5.44%
Oct-25-20 08:30AM  
Sep-14-20 11:43AM  
Sep-08-20 08:00AM  
Aug-13-20 09:00AM  
Jul-28-20 09:00AM  
Jul-20-20 09:00AM  
Jul-10-20 07:25AM  
07:00AM  
Jul-06-20 09:00AM  
Jul-02-20 05:00PM  
Jun-01-20 08:30AM  
May-04-20 06:45AM  
Apr-28-20 06:32AM  
Apr-23-20 07:00AM  
Apr-21-20 06:00PM  
Apr-20-20 06:30AM  
Mar-23-20 06:28AM  
Mar-02-20 07:00AM  
Feb-12-20 07:00AM  
Feb-11-20 07:16AM  
Jan-06-20 07:00AM  
Jan-02-20 05:25AM  
Dec-23-19 07:00AM  
Dec-16-19 06:45AM  
Dec-13-19 05:45PM  
06:45AM  
Dec-02-19 07:00AM  
Nov-26-19 07:00AM  
Nov-22-19 07:00AM  
Nov-20-19 07:00AM  
Nov-07-19 07:00AM  
Nov-05-19 07:00AM  
Nov-03-19 07:38AM  
Oct-28-19 07:00AM  
Oct-25-19 07:00AM  
Oct-22-19 07:00AM  
Oct-15-19 07:00AM  
Oct-10-19 07:00AM  
Sep-23-19 07:00AM  
Sep-19-19 07:53AM  
07:00AM  
Sep-16-19 07:00AM  
Aug-26-19 07:00AM  
Jul-29-19 07:00AM  
Jul-24-19 07:00AM  
Jul-23-19 01:22PM  
Jul-22-19 07:00AM  
Jul-17-19 12:25PM  
07:00AM  
Jul-16-19 07:00AM  
May-29-19 07:00AM  
May-24-19 02:56PM  
May-21-19 07:00AM  
May-13-19 07:00AM  
May-02-19 07:00AM  
Apr-17-19 07:00AM  
Apr-11-19 07:00AM  
Apr-03-19 02:00PM  
Mar-27-19 07:00AM  
Mar-25-19 07:00AM  
Mar-14-19 07:00AM  
Mar-13-19 12:48PM  
Mar-04-19 07:00AM  
Feb-28-19 07:00AM  
Feb-25-19 07:00AM  
Feb-21-19 07:00AM  
Feb-13-19 07:00AM  
Feb-05-19 11:17AM  
Jan-25-19 07:00AM  
Jan-24-19 07:00AM  
Jan-16-19 07:30AM  
Dec-26-18 11:05AM  
Dec-19-18 07:00AM  
Dec-03-18 07:00AM  
Nov-15-18 07:00AM  
Nov-12-18 07:00AM  
Oct-29-18 07:00AM  
Oct-24-18 07:00AM  
Oct-22-18 07:00AM  
Oct-17-18 07:00AM  
Oct-16-18 10:59AM  
Oct-15-18 07:00AM  
Oct-11-18 07:00AM  
Oct-05-18 07:00AM  
Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of cancer, which is based on the body's immune response to the presence of a malignancy. It is also developing a vaccine against triple negative breast cancer; and chimeric endocrine receptor T-cell technology focused on treating ovarian cancer. Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology; and with OntoChem GmbH to develop novel Covid-19 therapeutics. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Titterton Lewis H jrDirectorSep 11Buy2.0840,00083,2001,020,326Sep 14 09:29 AM
KUMAR AMITChief Executive OfficerSep 11Buy2.1128,00059,080262,000Sep 11 11:58 AM
Titterton Lewis H jrDirectorJun 16Buy2.2724,50055,615980,326Jun 17 10:30 AM
Titterton Lewis H jrDirectorJun 15Buy2.2731,08370,558955,826Jun 16 11:43 AM
KUMAR AMITChief Executive OfficerJun 12Buy2.0320,00040,600234,000Jun 12 10:48 AM
Titterton Lewis H jrDirectorMar 13Buy2.125,79912,294924,743Mar 17 03:46 PM
KUMAR AMITChief Executive OfficerMar 12Buy1.8220,00036,400214,000Mar 12 10:26 AM
Baskies Arnold MDirectorMar 12Buy1.8410,00018,40041,000Mar 12 01:38 PM
Baskies Arnold MDirectorMar 06Buy2.7110,00027,10031,000Mar 10 02:54 PM
Baskies Arnold MDirectorJan 17Buy3.5310,00035,30021,000Jan 21 11:45 AM
Titterton Lewis H jrDirectorJan 15Buy3.325,00016,600918,944Jan 16 11:22 AM
Titterton Lewis H jrDirectorJan 14Buy3.227,40023,828913,944Jan 15 10:57 AM
KUMAR AMITChief Executive OfficerJan 14Buy2.9920,00059,800194,000Jan 14 10:47 AM
ASX ASE Technology Holding Co., Ltd. daily Stock Chart
ASX [NYSE]
ASE Technology Holding Co., Ltd.
Index- P/E11.98 EPS (ttm)0.37 Insider Own- Shs Outstand2.13B Perf Week5.66%
Market Cap9.74B Forward P/E11.20 EPS next Y0.40 Insider Trans- Shs Float1.58B Perf Month11.72%
Income799.40M PEG0.35 EPS next Q0.09 Inst Own5.00% Short Float0.04% Perf Quarter-9.86%
Sales15.27B P/S0.64 EPS this Y-33.50% Inst Trans-1.04% Short Ratio0.81 Perf Half Y2.99%
Book/sh3.27 P/B1.37 EPS next Y15.94% ROA4.10% Target Price6.01 Perf Year-12.16%
Cash/sh1.02 P/C4.40 EPS next 5Y34.20% ROE11.40% 52W Range3.17 - 5.70 Perf YTD-19.42%
Dividend0.14 P/FCF3.59 EPS past 5Y- ROI4.20% 52W High-21.40% Beta-
Dividend %3.12% Quick Ratio0.90 Sales past 5Y- Gross Margin16.90% 52W Low41.32% ATR0.09
Employees95448 Current Ratio1.20 Sales Q/Q18.50% Oper. Margin7.10% RSI (14)64.48 Volatility1.76% 1.47%
OptionableNo Debt/Eq1.07 EPS Q/Q156.90% Profit Margin5.20% Rel Volume0.67 Prev Close4.45
ShortableYes LT Debt/Eq0.80 Earnings- Payout- Avg Volume699.40K Price4.48
Recom1.70 SMA206.39% SMA506.57% SMA2001.13% Volume466,076 Change0.67%
Sep-24-19Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-04-19Initiated Goldman Buy
Aug-01-19Upgrade Macquarie Underperform → Outperform
May-14-19Reiterated Cowen Market Perform $31 → $30
Jan-02-19Downgrade Macquarie Neutral → Underperform
Oct-10-18Downgrade JP Morgan Overweight → Neutral
Oct-08-20 03:00AM  
Sep-09-20 03:00AM  
Sep-02-20 01:21PM  
Aug-10-20 03:00AM  
Jul-31-20 09:32PM  
07:48AM  
02:00AM  
Jul-30-20 01:00PM  
11:52AM  
Jul-28-20 11:36AM  
Jul-21-20 12:19PM  
Jul-09-20 03:00AM  
Jun-25-20 08:30AM  
Jun-23-20 04:00PM  
Jun-10-20 09:40AM  
Jun-09-20 03:00AM  
Jun-08-20 02:58PM  
Jun-04-20 08:05AM  
Jun-03-20 11:40AM  
Jun-01-20 12:00PM  
11:16AM  
May-27-20 09:11AM  
May-22-20 10:41AM  
08:03AM  
May-19-20 08:45AM  
08:43AM  
May-18-20 11:40AM  
07:45AM  
May-14-20 10:21AM  
May-13-20 09:48AM  
May-11-20 07:11AM  
May-08-20 03:00AM  
May-05-20 10:08AM  
May-04-20 11:08AM  
07:43AM  
May-01-20 12:00PM  
Apr-29-20 05:30PM  
03:00AM  
Apr-24-20 11:24AM  
Apr-16-20 05:45PM  
Apr-15-20 08:51AM  
Apr-10-20 03:00AM  
Apr-03-20 05:50PM  
Apr-01-20 03:00AM  
Mar-27-20 07:09AM  
Mar-25-20 06:33AM  
Mar-24-20 09:36AM  
Mar-23-20 09:02AM  
Mar-19-20 05:50PM  
02:08PM  
Mar-18-20 11:41AM  
11:41AM  
Mar-17-20 10:46AM  
Mar-12-20 12:00PM  
10:17AM  
Mar-11-20 11:40AM  
Mar-10-20 03:00AM  
Mar-05-20 03:00PM  
Feb-26-20 12:43PM  
Feb-24-20 11:40AM  
Feb-21-20 08:44AM  
Feb-10-20 10:05AM  
09:07AM  
02:00AM  
Feb-07-20 01:00AM  
Feb-06-20 12:00PM  
11:40AM  
Jan-21-20 09:00AM  
Jan-09-20 02:00AM  
Dec-16-19 07:18AM  
Dec-13-19 01:59AM  
Dec-10-19 02:00AM  
Dec-03-19 03:42PM  
Nov-08-19 02:00AM  
Oct-30-19 02:00AM  
Oct-29-19 12:26PM  
Oct-21-19 02:40PM  
Oct-09-19 03:00AM  
Sep-16-19 09:00AM  
Sep-10-19 03:00AM  
Aug-14-19 11:43PM  
Aug-09-19 03:00AM  
Jul-31-19 03:00AM  
Jul-09-19 03:00AM  
Jun-10-19 03:00AM  
May-09-19 07:34AM  
03:44AM  
03:00AM  
Apr-30-19 05:03AM  
03:00AM  
Apr-29-19 03:00AM  
Apr-16-19 02:31PM  
Apr-10-19 03:23AM  
03:00AM  
Apr-01-19 08:59AM  
Mar-26-19 09:10AM  
Mar-25-19 08:35AM  
Mar-12-19 11:36AM  
Mar-08-19 02:00AM  
Mar-05-19 04:32PM  
ASE Technology Holding Co., Ltd. provides a range of semiconductors packaging and testing, and electronic manufacturing services in the United States, Taiwan, Asia, Europe, and internationally. The company offers packaging services, including flip chip ball grid array (BGA), flip chip chip scale package (CSP), advanced chip scale packages, quad flat packages, thin quad flat packages, bump chip carrier and quad flat no-lead (QFN) packages, advanced QFN packages, plastic BGAs, and 3D chip packages; stacked die solutions in various package types; and copper and silver wire bonding solutions, as well as module-based solutions. It also provides advanced packages, such as flip chip BGA; heat-spreader FCBGA; flip-chip CSP; hybrid FCCSP; flip chip package in package and package on package (POP); advanced single sided substrate; high-bandwidth POP; fan-out wafer level packaging; SESUB; and substrate interposer packages. In addition, the company offers IC wire bonding packages; system-in-package products (SiP) and modules; and interconnect materials, as well as assembles automotive electronic products. Further, it provides a range of semiconductor testing services, including front-end engineering testing, wafer probing, logic/mixed-signal/RF module and SiP/MEMS/discrete final testing, and other test-related services, as well as drop shipment services. Additionally, the company develops, constructs, sells, leases, and manages real estate properties; produces substrates; offers information software, equipment leasing, financing, investment advisory, warehousing management, logistics, and after sales services; manufactures computer assistance systems and related peripherals, electronic components, communication peripherals, telecommunications equipment, motherboards, and car components; imports and exports various products and technology. ASE Technology Holding Co., Ltd. was founded in 1984 and is based in Kaohsiung, Taiwan.
ATAX America First Multifamily Investors, L.P. daily Stock Chart
ATAX [NASD]
America First Multifamily Investors, L.P.
Index- P/E10.36 EPS (ttm)0.39 Insider Own0.80% Shs Outstand60.55M Perf Week-1.95%
Market Cap236.09M Forward P/E5.29 EPS next Y0.76 Insider Trans19.95% Shs Float58.38M Perf Month0.50%
Income23.50M PEG- EPS next Q0.06 Inst Own8.80% Short Float0.16% Perf Quarter7.77%
Sales74.70M P/S3.16 EPS this Y-29.50% Inst Trans-0.54% Short Ratio0.64 Perf Half Y-20.24%
Book/sh5.73 P/B0.70 EPS next Y230.43% ROA2.30% Target Price- Perf Year-47.99%
Cash/sh0.61 P/C6.54 EPS next 5Y- ROE6.90% 52W Range3.52 - 8.17 Perf YTD-47.79%
Dividend0.24 P/FCF- EPS past 5Y11.40% ROI3.30% 52W High-50.80% Beta0.60
Dividend %5.97% Quick Ratio- Sales past 5Y11.40% Gross Margin69.20% 52W Low14.20% ATR0.12
Employees- Current Ratio- Sales Q/Q1.40% Oper. Margin35.30% RSI (14)44.30 Volatility3.30% 3.30%
OptionableYes Debt/Eq1.68 EPS Q/Q22.40% Profit Margin31.50% Rel Volume1.11 Prev Close3.90
ShortableYes LT Debt/Eq1.62 EarningsNov 04 AMC Payout129.00% Avg Volume145.68K Price4.02
Recom2.00 SMA20-1.42% SMA50-4.45% SMA200-22.29% Volume161,887 Change3.08%
Sep-01-17Downgrade Oppenheimer Outperform → Perform
Feb-12-14Initiated Oppenheimer Outperform $6.50
Oct-21-20 08:30AM  
Sep-30-20 08:15AM  
Sep-16-20 04:15PM  
Sep-14-20 04:15PM  
Aug-04-20 08:15AM  
Jul-30-20 08:15AM  
Jul-22-20 08:15AM  
May-22-20 08:30AM  
May-11-20 07:13AM  
May-06-20 08:15AM  
May-04-20 04:40PM  
Apr-23-20 04:15PM  
Mar-22-20 10:46PM  
Feb-28-20 08:30AM  
Feb-26-20 08:15AM  
Feb-13-20 04:15PM  
Feb-11-20 04:15PM  
Jan-13-20 02:23PM  
Dec-23-19 02:54PM  
Dec-20-19 08:30AM  
Dec-18-19 04:05PM  
Dec-06-19 04:30PM  
Nov-21-19 04:49PM  
Nov-01-19 08:00AM  
Oct-17-19 04:05PM  
Sep-11-19 09:00AM  
08:00AM  
Aug-30-19 09:00AM  
Aug-14-19 12:33PM  
Aug-06-19 01:23AM  
Aug-05-19 04:05PM  
Aug-02-19 08:00AM  
Jul-31-19 04:15PM  
Jul-22-19 04:05PM  
Jul-16-19 04:05PM  
May-14-19 04:32AM  
May-06-19 09:23PM  
May-03-19 04:15PM  
Apr-17-19 08:00AM  
Mar-05-19 04:09AM  
Feb-28-19 07:10PM  
08:00AM  
Feb-22-19 02:59PM  
Feb-07-19 08:00AM  
Nov-07-18 06:58AM  
02:44AM  
Nov-05-18 08:55AM  
08:00AM  
Oct-26-18 08:10AM  
Oct-17-18 08:00AM  
Oct-01-18 08:00AM  
Sep-27-18 07:30AM  
Sep-12-18 12:21PM  
Aug-29-18 02:00PM  
Aug-17-18 06:15PM  
Aug-13-18 06:54PM  
02:30PM  
Aug-09-18 08:30AM  
Aug-06-18 07:40PM  
06:37PM  
04:32PM  
Jul-23-18 04:15PM  
Jul-20-18 08:00AM  
Jul-02-18 10:20AM  
05:10AM  
Jun-27-18 08:15AM  
Jun-21-18 09:30AM  
Jun-12-18 04:41AM  
Jun-07-18 08:38AM  
Jun-04-18 08:25AM  
07:56AM  
May-30-18 07:30AM  
May-07-18 12:00PM  
09:21AM  
08:15AM  
Apr-18-18 04:15PM  
Apr-11-18 07:45AM  
Mar-28-18 06:28AM  
Mar-21-18 04:54PM  
Mar-14-18 07:45AM  
Mar-02-18 08:15AM  
Mar-01-18 12:15PM  
Feb-28-18 10:23AM  
08:15AM  
Feb-09-18 04:05PM  
Dec-29-17 07:23AM  
Dec-12-17 08:10AM  
Dec-05-17 04:15PM  
Dec-01-17 04:15PM  
Nov-28-17 07:20AM  
Nov-27-17 04:15PM  
Nov-07-17 12:40PM  
Nov-06-17 10:49AM  
08:00AM  
Nov-02-17 08:32AM  
Oct-26-17 05:00PM  
Oct-23-17 08:10AM  
Oct-19-17 08:00AM  
Oct-09-17 08:15AM  
Oct-04-17 08:00AM  
America First Multifamily Investors, L.P. acquires, holds, sells, and deals in a portfolio of mortgage revenue bonds (MRBs) that are issued to provide construction or permanent financing for multifamily and student housing, and commercial properties. It operates through four segments: Mortgage Revenue Bond Investments, MF Properties, Public housing Capital Fund Trust, and Other Investments. As of December 31, 2019, the company owned 76 MRBs, of which various bonds were issued by state and local housing authorities in order to provide construction or permanent financing for 66 residential properties comprising a total of 10,871 rental units located in 13 states in the United States. America First Capital Associates Limited Partnership Two serves as the general partner of the company. The company was founded in 1998 and is based in Omaha, Nebraska.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROSENBERG STEPHENDirectorAug 19Buy4.6642,500198,19942,500Aug 24 05:01 PM
Rogozinski KennethChief Investment OfficerAug 19Buy4.588,60039,40721,908Aug 19 05:08 PM
Baevsky JeffreyDirectorAug 11Buy4.685,00023,40010,700Aug 12 10:07 AM
Daffer Chad LChief Executive OfficerAug 10Buy4.4816,74075,045415,239Aug 11 02:40 PM
Rogozinski KennethChief Investment OfficerAug 06Buy4.335,30822,97113,308Aug 10 02:16 PM
Rogozinski KennethChief Investment OfficerMar 16Buy6.153,00018,4578,000Mar 17 08:30 AM
Daffer Chad LChief Executive OfficerMar 16Buy6.046,50039,270323,499Mar 17 08:30 AM
Rogozinski KennethChief Investment OfficerMar 12Buy6.875,00034,3455,000Mar 13 09:32 AM
Daffer Chad LChief Executive OfficerMar 03Buy7.6913,200101,554316,999Mar 04 04:30 PM
BBI Brickell Biotech, Inc. daily Stock Chart
BBI [NASD]
Brickell Biotech, Inc.
Index- P/E- EPS (ttm)-3.90 Insider Own2.30% Shs Outstand27.79M Perf Week-44.31%
Market Cap20.00M Forward P/E- EPS next Y-0.81 Insider Trans6.30% Shs Float25.05M Perf Month-33.47%
Income-24.90M PEG- EPS next Q-0.19 Inst Own21.10% Short Float1.03% Perf Quarter-45.32%
Sales3.50M P/S5.71 EPS this Y13.60% Inst Trans1.01% Short Ratio0.13 Perf Half Y-56.39%
Book/sh1.68 P/B0.31 EPS next Y- ROA-110.90% Target Price- Perf Year-82.04%
Cash/sh0.56 P/C0.93 EPS next 5Y- ROE-193.40% 52W Range0.71 - 4.00 Perf YTD-65.41%
Dividend- P/FCF- EPS past 5Y19.10% ROI-291.40% 52W High-87.03% Beta-0.19
Dividend %- Quick Ratio3.80 Sales past 5Y-12.30% Gross Margin- 52W Low-26.93% ATR0.08
Employees15 Current Ratio3.80 Sales Q/Q-76.90% Oper. Margin- RSI (14)24.89 Volatility11.85% 8.11%
OptionableNo Debt/Eq0.02 EPS Q/Q93.30% Profit Margin- Rel Volume7.79 Prev Close0.72
ShortableNo LT Debt/Eq0.01 EarningsAug 12 AMC Payout- Avg Volume1.98M Price0.52
Recom1.50 SMA20-41.79% SMA50-39.16% SMA200-57.71% Volume15,432,812 Change-27.94%
Aug-28-20Initiated Lake Street Buy $6
Aug-25-20Initiated Oppenheimer Outperform $5
Oct-22-20 08:00PM  
Sep-29-20 10:30AM  
Sep-25-20 07:00AM  
Sep-10-20 04:05PM  
Sep-08-20 07:30AM  
Aug-31-20 04:05PM  
Aug-12-20 04:01PM  
Aug-03-20 04:05PM  
Jun-17-20 10:00PM  
Jun-15-20 06:30AM  
May-31-20 08:04AM  
May-13-20 04:01PM  
May-04-20 04:05PM  
Mar-18-20 04:01PM  
02:30PM  
Mar-09-20 04:05PM  
Mar-04-20 06:30AM  
Feb-20-20 11:43AM  
06:30AM  
Feb-18-20 06:30AM  
Jan-10-20 04:05PM  
Nov-13-19 04:05PM  
Oct-30-19 04:42PM  
Sep-03-19 06:45AM  
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in Phase III clinical trial for patients with axillary hyperhidrosis. It is also developing therapeutics for cutaneous T-cell lymphoma, psoriasis, and other dermatological conditions. Brickell Biotech, Inc. has collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19 in the United States. The company was founded in 2009 and is based in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McAvoy David R.General Counsel and CCOSep 18Buy0.846,0005,0396,000Sep 21 04:19 PM
McAvoy David R.General Counsel and CCOSep 18Buy0.8316,52613,71375,883Sep 21 04:19 PM
VERU DENNISON TDirectorSep 16Buy0.8014,64511,75850,810Sep 17 05:07 PM
VERU DENNISON TDirectorSep 15Buy0.8115,35512,41636,165Sep 17 05:07 PM
BBQ BBQ Holdings, Inc. daily Stock Chart
BBQ [NASD]
BBQ Holdings, Inc.
Index- P/E6.79 EPS (ttm)0.61 Insider Own0.90% Shs Outstand9.14M Perf Week-4.16%
Market Cap38.51M Forward P/E- EPS next Y-0.09 Insider Trans365.58% Shs Float8.90M Perf Month31.33%
Income5.70M PEG0.68 EPS next Q-0.08 Inst Own72.20% Short Float0.23% Perf Quarter31.73%
Sales97.50M P/S0.39 EPS this Y-112.70% Inst Trans4.35% Short Ratio0.40 Perf Half Y77.45%
Book/sh3.29 P/B1.26 EPS next Y75.70% ROA5.20% Target Price- Perf Year-17.00%
Cash/sh- P/C- EPS next 5Y10.00% ROE20.20% 52W Range1.51 - 5.24 Perf YTD5.60%
Dividend- P/FCF- EPS past 5Y-17.40% ROI-3.30% 52W High-20.80% Beta2.14
Dividend %- Quick Ratio1.00 Sales past 5Y-9.00% Gross Margin12.30% 52W Low174.83% ATR0.33
Employees172 Current Ratio1.00 Sales Q/Q28.40% Oper. Margin2.10% RSI (14)53.53 Volatility5.03% 8.48%
OptionableNo Debt/Eq0.96 EPS Q/Q-710.40% Profit Margin5.80% Rel Volume0.01 Prev Close4.15
ShortableYes LT Debt/Eq0.66 Earnings- Payout0.00% Avg Volume50.76K Price4.15
Recom3.00 SMA208.14% SMA502.72% SMA20021.20% Volume593 Change0.00%
Oct-12-20 09:00AM  
Aug-12-20 04:17PM  
Jun-04-20 07:25PM  
May-29-20 04:30PM  
May-13-20 04:30PM  
Mar-27-20 04:30PM  
Mar-11-20 08:16AM  
Feb-24-20 08:58AM  
Feb-13-20 03:53PM  
08:26AM  
Feb-12-20 07:17AM  
Feb-03-20 03:18PM  
Jan-09-20 04:01PM  
Dec-23-19 07:56PM  
Nov-12-19 04:01PM  
Nov-11-19 04:01PM  
Oct-04-19 11:13AM  
Oct-02-19 07:50AM  
BBQ Holdings, Inc. develops, owns, operates, and franchises barbeque restaurants under the Famous Dave's name in the United States, Canada, and the United Arab Emirates. It offers smoked, barbequed, and grilled meats, as well as entree items and side dishes that are prepared using prepared proprietary seasonings, sauces, and mixes. The company operates full-service and counter-service restaurants. As of March 27, 2020, it had 139 restaurants, including 48 company-owned restaurants and 91 franchise-operated restaurants in 28 states and three countries. The company was founded in 1994 and is based in Minnetonka, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kanen DavidDirectorSep 04Buy4.249,00038,156563,905Sep 08 06:19 AM
Kanen DavidDirectorAug 28Buy4.269,40640,070554,905Aug 31 08:08 AM
Kanen DavidDirectorAug 20Buy3.4536,986127,7201,019,806Aug 21 08:09 AM
Kanen DavidDirectorAug 19Buy3.15249,937787,402545,499Aug 20 03:17 PM
Kanen DavidDirectorNov 26Sale4.8857,500280,600990,582Nov 29 06:39 PM
BKTI BK Technologies Corporation daily Stock Chart
BKTI [AMEX]
BK Technologies Corporation
Index- P/E- EPS (ttm)-0.20 Insider Own2.00% Shs Outstand12.50M Perf Week2.41%
Market Cap35.40M Forward P/E- EPS next Y- Insider Trans121.62% Shs Float10.96M Perf Month-3.56%
Income-2.60M PEG- EPS next Q- Inst Own68.60% Short Float0.06% Perf Quarter-7.17%
Sales40.00M P/S0.89 EPS this Y- Inst Trans0.12% Short Ratio0.42 Perf Half Y26.27%
Book/sh1.69 P/B1.76 EPS next Y- ROA-6.90% Target Price- Perf Year-13.75%
Cash/sh0.58 P/C5.13 EPS next 5Y22.50% ROE-11.30% 52W Range1.17 - 3.63 Perf YTD-3.87%
Dividend0.08 P/FCF- EPS past 5Y-30.30% ROI-14.30% 52W High-17.82% Beta1.45
Dividend %2.68% Quick Ratio1.50 Sales past 5Y5.30% Gross Margin39.40% 52W Low154.70% ATR0.16
Employees111 Current Ratio2.70 Sales Q/Q-25.60% Oper. Margin-7.40% RSI (14)48.78 Volatility3.48% 4.08%
OptionableNo Debt/Eq0.02 EPS Q/Q-24.50% Profit Margin-6.40% Rel Volume0.15 Prev Close2.83
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume14.61K Price2.98
Recom- SMA20-1.26% SMA50-2.81% SMA2006.27% Volume2,206 Change5.30%
Oct-14-20 04:30PM  
Oct-06-20 08:30AM  
Sep-17-20 03:00PM  
Aug-31-20 05:00PM  
04:30PM  
Aug-18-20 08:30AM  
Aug-12-20 05:30PM  
Aug-05-20 04:25PM  
04:15PM  
Jul-30-20 08:30AM  
Jun-29-20 06:12AM  
Jun-10-20 04:15PM  
May-27-20 09:15AM  
May-25-20 06:50AM  
May-13-20 04:15PM  
May-07-20 08:30AM  
Mar-26-20 10:45AM  
Mar-17-20 09:30AM  
Mar-04-20 04:15PM  
Mar-03-20 08:30AM  
Mar-02-20 04:15PM  
Feb-27-20 08:30AM  
Feb-05-20 08:30AM  
Jan-15-20 04:30PM  
Dec-30-19 04:55AM  
Dec-05-19 03:50PM  
Nov-11-19 08:00AM  
Nov-06-19 04:15PM  
Oct-31-19 08:30AM  
07:00AM  
Sep-12-19 05:00PM  
Aug-06-19 04:15PM  
Jul-31-19 08:00AM  
Jul-11-19 08:30AM  
Jul-10-19 08:00AM  
Jun-10-19 04:15PM  
May-08-19 04:15PM  
May-02-19 08:30AM  
Mar-28-19 01:15PM  
Mar-11-19 06:00AM  
Mar-06-19 06:00AM  
Feb-28-19 07:00AM  
Feb-27-19 04:15PM  
Feb-21-19 08:30AM  
Dec-07-18 03:15PM  
Nov-27-18 11:54AM  
Nov-07-18 03:15PM  
Nov-01-18 08:30AM  
Sep-27-18 08:30AM  
Sep-20-18 09:17AM  
Sep-06-18 04:15PM  
Aug-02-18 07:00AM  
Aug-01-18 04:30PM  
Jul-25-18 08:15AM  
Jun-26-18 01:44PM  
08:30AM  
Jun-08-18 06:36PM  
BK Technologies Corporation, through its subsidiary, BK Technologies, Inc., designs, manufactures, and markets wireless communications products in the United States and internationally. The company offers two-way land mobile radios (LMR), repeaters, base stations, and related components and subsystems under BK Technologies, BK Radio, and RELM brand names. Its BK Technologies and BK Radio branded products include LMR equipment for professional radio users primarily in government, public safety, and military applications, as well as P-25 digital products; and RELM branded products provide two-way communications for commercial and industrial concerns, such as hotels, construction firms, schools, and transportation services. The company was incorporated in 1997 and is headquartered in West Melbourne, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fundamental Global Investors, DirectorSep 11Buy3.134001,2501,411,756Sep 14 05:32 PM
Fundamental Global Investors, DirectorSep 10Buy3.178992,8541,411,356Sep 14 05:32 PM
Fundamental Global Investors, DirectorSep 09Buy3.291,6655,4751,410,457Sep 09 09:14 PM
Fundamental Global Investors, DirectorSep 08Buy3.167572,3891,408,792Sep 09 09:14 PM
Fundamental Global Investors, DirectorSep 04Buy3.143109741,408,035Sep 08 02:32 PM
Fundamental Global Investors, DirectorSep 03Buy3.091,4914,6011,407,725Sep 08 02:32 PM
Fundamental Global Investors, DirectorSep 02Buy3.009922,9761,406,234Sep 02 07:25 PM
Fundamental Global Investors, DirectorSep 01Buy3.103029351,405,242Sep 02 07:25 PM
Fundamental Global Investors, DirectorAug 31Buy3.143119781,404,940Sep 02 07:25 PM
Fundamental Global Investors, DirectorAug 28Buy3.183,42410,9041,404,629Aug 31 02:10 PM
Fundamental Global Investors, DirectorAug 27Buy3.041,7875,4351,401,205Aug 31 02:10 PM
Fundamental Global Investors, DirectorAug 26Buy3.002,0036,0031,399,418Aug 26 07:27 PM
Fundamental Global Investors, DirectorAug 25Buy3.019002,7131,397,415Aug 26 07:27 PM
Fundamental Global Investors, DirectorAug 24Buy3.081,2353,8031,396,515Aug 26 07:27 PM
Fundamental Global Investors, DirectorAug 21Buy3.111,3004,0401,395,280Aug 24 05:28 PM
Fundamental Global Investors, DirectorAug 20Buy3.133,60011,2581,393,980Aug 24 05:28 PM
Fundamental Global Investors, DirectorAug 19Buy3.162,7758,7631,390,380Aug 19 07:34 PM
Fundamental Global Investors, DirectorAug 18Buy3.265,18016,8931,387,605Aug 19 07:34 PM
Fundamental Global Investors, DirectorAug 17Buy3.198332,6571,382,425Aug 19 07:34 PM
Fundamental Global Investors, DirectorAug 14Buy3.181,4744,6871,381,592Aug 17 07:39 PM
Fundamental Global Investors, DirectorAug 13Buy3.213,79512,1731,380,118Aug 17 07:39 PM
Fundamental Global Investors, DirectorAug 12Buy3.251,3014,2281,376,323Aug 12 08:22 PM
Fundamental Global Investors, DirectorAug 11Buy3.231,4304,6231,375,022Aug 12 08:22 PM
Fundamental Global Investors, DirectorAug 10Buy3.353,61112,0801,373,592Aug 12 08:22 PM
Fundamental Global Investors, DirectorAug 07Buy3.392,2767,7101,369,981Aug 10 03:28 PM
Fundamental Global Investors, DirectorAug 06Buy3.441,9196,5991,367,705Aug 10 03:28 PM
Fundamental Global Investors, DirectorAug 05Buy3.382961,0001,365,786Aug 05 07:15 PM
Fundamental Global Investors, DirectorAug 04Buy3.294161,3701,365,490Aug 05 07:15 PM
Fundamental Global Investors, DirectorAug 03Buy3.132949201,365,074Aug 05 07:15 PM
Fundamental Global Investors, DirectorJul 31Buy3.151,4714,6361,364,780Aug 03 04:18 PM
Fundamental Global Investors, DirectorJul 30Buy3.218592,7621,363,309Aug 03 04:18 PM
Fundamental Global Investors, DirectorJul 29Buy3.277092,3201,362,450Jul 29 09:03 PM
Fundamental Global Investors, DirectorJul 28Buy3.243401,1011,361,741Jul 29 09:03 PM
Fundamental Global Investors, DirectorJul 27Buy3.192,5368,0861,361,401Jul 29 09:03 PM
Fundamental Global Investors, DirectorJul 24Buy3.201,1833,7801,358,865Jul 27 03:46 PM
Fundamental Global Investors, DirectorJul 23Buy3.287672,5171,357,682Jul 27 03:46 PM
Fundamental Global Investors, DirectorJul 22Buy3.214441,4271,356,915Jul 22 09:40 PM
Fundamental Global Investors, DirectorJul 21Buy3.302,2337,3711,356,471Jul 22 09:40 PM
Fundamental Global Investors, DirectorJul 20Buy3.322899611,354,238Jul 22 09:40 PM
Fundamental Global Investors, DirectorJul 17Buy3.361936491,353,949Jul 20 04:29 PM
Fundamental Global Investors, DirectorJul 16Buy3.396392,1641,353,756Jul 20 04:29 PM
Fundamental Global Investors, DirectorJul 15Buy3.347812,6121,353,117Jul 15 08:48 PM
Fundamental Global Investors, DirectorJul 14Buy3.261,5054,9041,352,336Jul 15 08:48 PM
Fundamental Global Investors, DirectorJul 10Buy3.388002,7071,350,831Jul 13 03:55 PM
Fundamental Global Investors, DirectorJul 09Buy3.361,0003,3601,350,031Jul 13 03:55 PM
Fundamental Global Investors, DirectorJul 08Buy3.411,3374,5531,349,031Jul 08 07:40 PM
Fundamental Global Investors, DirectorJul 07Buy3.479163,1811,347,694Jul 08 07:40 PM
Fundamental Global Investors, DirectorJul 06Buy3.443,30511,3691,346,778Jul 08 07:40 PM
Fundamental Global Investors, DirectorJul 02Buy3.492,2837,9601,343,473Jul 06 03:27 PM
Fundamental Global Investors, DirectorJul 01Buy3.461,5645,4041,341,190Jul 01 07:10 PM
Fundamental Global Investors, DirectorJun 30Buy3.431,9006,5251,339,626Jul 01 07:10 PM
Fundamental Global Investors, DirectorJun 29Buy3.425001,7101,337,726Jul 01 07:10 PM
Fundamental Global Investors, DirectorJun 26Buy3.496552,2831,337,226Jun 29 06:33 PM
Fundamental Global Investors, DirectorJun 25Buy3.258002,6041,336,571Jun 29 06:33 PM
Fundamental Global Investors, DirectorJun 24Buy3.251,8946,1611,335,771Jun 24 07:10 PM
Fundamental Global Investors, DirectorJun 23Buy3.301,8536,1161,333,877Jun 24 07:10 PM
Fundamental Global Investors, DirectorJun 22Buy3.357002,3461,332,024Jun 24 07:10 PM
Fundamental Global Investors, DirectorJun 19Buy3.482,7009,3881,331,324Jun 22 04:52 PM
Fundamental Global Investors, DirectorJun 18Buy3.423,60112,3221,328,624Jun 22 04:52 PM
Fundamental Global Investors, DirectorJun 17Buy3.468,85030,6111,325,023Jun 17 09:49 PM
Fundamental Global Investors, DirectorJun 16Buy3.291,5004,9341,316,173Jun 17 09:49 PM
Fundamental Global Investors, DirectorJun 15Buy3.218872,8511,314,673Jun 17 09:49 PM
Fundamental Global Investors, DirectorJun 12Buy3.311,4284,7221,313,786Jun 15 03:40 PM
Fundamental Global Investors, DirectorJun 11Buy3.186,90121,9361,312,358Jun 15 03:40 PM
Fundamental Global Investors, DirectorJun 10Buy3.276,29120,5571,305,457Jun 10 07:33 PM
Fundamental Global Investors, DirectorJun 09Buy3.272,0036,5521,299,166Jun 10 07:33 PM
Fundamental Global Investors, DirectorJun 08Buy3.235,48617,7011,297,163Jun 10 07:33 PM
Fundamental Global Investors, DirectorJun 05Buy3.236,35120,4831,291,677Jun 08 04:19 PM
Fundamental Global Investors, DirectorJun 04Buy3.366,35121,3081,285,326Jun 08 04:19 PM
Fundamental Global Investors, DirectorJun 03Buy3.366,35121,3671,280,880Jun 03 08:14 PM
Fundamental Global Investors, DirectorJun 02Buy3.356,35121,2541,276,434Jun 03 08:14 PM
Fundamental Global Investors, DirectorJun 01Buy3.096,35119,6261,271,988Jun 03 08:14 PM
Fundamental Global Investors, DirectorMay 29Buy2.845,96416,9321,267,542Jun 01 04:17 PM
Fundamental Global Investors, DirectorMay 28Buy3.005,96417,9031,263,367Jun 01 04:17 PM
Fundamental Global Investors, DirectorMay 27Buy2.955,96417,5841,259,192May 27 07:18 PM
Fundamental Global Investors, DirectorMay 26Buy2.905,96417,3211,255,017May 27 07:18 PM
Fundamental Global Investors, DirectorMay 22Buy2.865,57715,9661,250,842May 26 01:33 PM
Fundamental Global Investors, DirectorMay 21Buy2.915,57716,2561,246,902May 26 01:33 PM
Fundamental Global Investors, DirectorMay 20Buy2.892,0365,8831,242,998May 20 06:42 PM
Fundamental Global Investors, DirectorMay 19Buy2.885,57716,0441,241,573May 20 06:42 PM
Fundamental Global Investors, DirectorMay 18Buy2.725,57715,1741,237,669May 20 06:42 PM
Fundamental Global Investors, DirectorMay 15Buy2.644,89912,9511,233,765May 18 05:09 PM
Fundamental Global Investors, DirectorMay 14Buy2.675,07813,5791,230,336May 18 05:09 PM
Fundamental Global Investors, DirectorMay 13Buy2.605,40014,0491,226,781May 13 07:53 PM
Fundamental Global Investors, DirectorMay 12Buy2.615,74414,9911,223,001May 13 07:53 PM
Fundamental Global Investors, DirectorMay 11Buy2.767,38720,3841,218,980May 13 07:53 PM
Fundamental Global Investors, DirectorMay 08Buy2.756,79118,6511,213,809May 11 06:09 PM
Fundamental Global Investors, DirectorMay 07Buy2.526,50916,4141,209,055May 11 06:09 PM
Fundamental Global Investors, DirectorMay 06Buy2.464931,2131,204,499May 06 07:27 PM
Fundamental Global Investors, DirectorMay 05Buy2.556,79117,3121,204,154May 06 07:27 PM
Fundamental Global Investors, DirectorMay 04Buy2.445,99114,6431,199,400May 06 07:27 PM
Fundamental Global Investors, DirectorMay 01Buy2.741,5094,1361,195,206May 04 03:55 PM
Fundamental Global Investors, DirectorApr 30Buy2.825,01814,1631,194,150May 04 03:55 PM
Fundamental Global Investors, DirectorApr 29Buy2.495,01812,4801,190,637Apr 29 08:45 PM
Fundamental Global Investors, DirectorApr 28Buy2.385,01811,9611,187,124Apr 29 08:45 PM
Fundamental Global Investors, DirectorApr 27Buy2.415,01812,0741,183,611Apr 27 07:54 PM
Fundamental Global Investors, DirectorApr 24Buy2.696,13216,4831,180,098Apr 27 07:54 PM
Fundamental Global Investors, DirectorApr 23Buy2.606,13215,9251,175,806Apr 27 07:54 PM
Fundamental Global Investors, DirectorApr 22Buy2.393,4148,1481,171,514Apr 22 08:40 PM
Fundamental Global Investors, DirectorApr 21Buy2.422,5206,0881,169,124Apr 22 08:40 PM
BRY Berry Corporation daily Stock Chart
BRY [NASD]
Berry Corporation
Index- P/E- EPS (ttm)-1.70 Insider Own0.70% Shs Outstand79.80M Perf Week-1.26%
Market Cap253.21M Forward P/E- EPS next Y-0.47 Insider Trans152.26% Shs Float79.02M Perf Month0.64%
Income-134.50M PEG- EPS next Q0.18 Inst Own97.50% Short Float1.33% Perf Quarter-39.09%
Sales685.50M P/S0.37 EPS this Y-12.10% Inst Trans0.93% Short Ratio3.22 Perf Half Y11.74%
Book/sh9.89 P/B0.32 EPS next Y-172.90% ROA-8.30% Target Price- Perf Year-68.15%
Cash/sh0.00 P/C- EPS next 5Y15.00% ROE-14.90% 52W Range1.82 - 11.72 Perf YTD-66.70%
Dividend- P/FCF1.29 EPS past 5Y- ROI5.70% 52W High-73.21% Beta-
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin68.30% 52W Low72.53% ATR0.22
Employees355 Current Ratio1.70 Sales Q/Q-80.30% Oper. Margin-19.30% RSI (14)44.48 Volatility5.70% 6.69%
OptionableYes Debt/Eq0.00 EPS Q/Q-307.80% Profit Margin-19.60% Rel Volume0.48 Prev Close3.17
ShortableYes LT Debt/Eq0.50 EarningsNov 03 AMC Payout- Avg Volume325.49K Price3.14
Recom2.60 SMA20-3.28% SMA50-12.72% SMA200-30.09% Volume156,386 Change-0.95%
Jul-27-20Initiated Seaport Global Securities Neutral
Mar-10-20Resumed Wells Fargo Equal Weight $5
Mar-09-20Downgrade Piper Sandler Overweight → Neutral $4.50
Feb-07-20Upgrade KeyBanc Capital Markets Underweight → Sector Weight
Nov-20-19Downgrade Wells Fargo Outperform → Market Perform $9
Nov-20-19Downgrade Tudor Pickering Buy → Hold
Nov-20-19Downgrade KeyBanc Capital Markets Sector Weight → Underweight
Nov-20-19Downgrade BMO Capital Markets Outperform → Market Perform $13 → $10
Nov-19-19Downgrade Johnson Rice Buy → Accumulate
Dec-20-18Initiated KeyBanc Capital Mkts Sector Weight
Dec-20-18Downgrade CapitalOne Overweight → Equal Weight
Dec-10-18Downgrade Evercore ISI Outperform → In-line
Aug-24-18Initiated Evercore ISI Outperform $18
Aug-24-18Initiated CapitalOne Overweight $24
Aug-21-18Initiated Tudor Pickering Buy
Aug-20-18Initiated Wells Fargo Outperform $17
Aug-20-18Initiated Piper Jaffray Overweight $25
Aug-20-18Initiated Johnson Rice Buy $20
Aug-20-18Initiated Goldman Buy $20
Oct-21-20 12:16PM  
Oct-16-20 07:14AM  
Oct-06-20 09:30AM  
Oct-05-20 02:45PM  
Oct-01-20 02:02PM  
Sep-30-20 01:45PM  
Sep-29-20 07:35PM  
04:05PM  
Sep-14-20 04:00PM  
Sep-11-20 06:24PM  
Sep-10-20 08:46AM  
Sep-09-20 03:34PM  
Sep-04-20 02:15PM  
Sep-02-20 01:50PM  
Sep-01-20 03:35PM  
Aug-31-20 12:15PM  
Aug-28-20 03:50PM  
Aug-27-20 01:25PM  
Aug-26-20 01:50PM  
Aug-25-20 01:05PM  
11:35AM  
Aug-24-20 02:10PM  
Aug-20-20 05:55PM  
10:45AM  
Aug-19-20 08:10PM  
Aug-04-20 06:55PM  
05:13PM  
Jul-28-20 12:33PM  
Jul-16-20 12:10PM  
Jul-14-20 11:24AM  
Jul-07-20 01:29PM  
Jul-01-20 01:35PM  
Jun-26-20 05:21PM  
Jun-17-20 02:15PM  
Jun-15-20 10:41AM  
Jun-12-20 10:12PM  
May-08-20 07:00PM  
May-06-20 06:46PM  
May-04-20 12:10PM  
Apr-30-20 06:29AM  
Apr-29-20 12:34PM  
Apr-08-20 01:43PM  
Apr-06-20 10:24PM  
05:45PM  
Apr-01-20 09:27AM  
Mar-30-20 05:45PM  
Mar-24-20 07:02AM  
Mar-10-20 06:57AM  
Mar-06-20 11:46AM  
07:51AM  
07:31AM  
Mar-04-20 12:00PM  
Mar-02-20 05:45AM  
Feb-26-20 09:07PM  
11:50AM  
Feb-25-20 09:59AM  
Feb-24-20 11:40AM  
Feb-20-20 05:45PM  
Feb-19-20 12:31PM  
Feb-13-20 05:45PM  
Feb-10-20 09:11AM  
Feb-07-20 01:12PM  
Feb-05-20 02:17PM  
09:15AM  
09:01AM  
Feb-04-20 10:10AM  
Feb-03-20 06:05AM  
Jan-31-20 08:30AM  
Jan-30-20 07:39AM  
Jan-28-20 06:39PM  
11:50AM  
Jan-27-20 06:16AM  
Jan-22-20 12:00PM  
09:20AM  
Jan-17-20 10:15AM  
Jan-15-20 08:05PM  
Jan-08-20 06:14AM  
Jan-06-20 10:13AM  
Dec-26-19 11:18AM  
Dec-10-19 10:48AM  
Dec-02-19 10:08AM  
Nov-20-19 03:38PM  
01:37PM  
09:36AM  
Nov-19-19 04:40PM  
03:34PM  
Nov-07-19 10:25AM  
09:00AM  
Nov-06-19 08:40AM  
04:55AM  
Nov-05-19 10:31AM  
08:07AM  
Nov-04-19 01:49PM  
09:26AM  
Oct-31-19 10:35AM  
Oct-30-19 11:50AM  
Oct-28-19 08:18PM  
Oct-09-19 12:09PM  
Oct-07-19 04:32PM  
08:22AM  
Berry Corporation, an independent upstream energy company, engages in the development and production of conventional oil reserves located in the western United States. The company's properties are located in the San Joaquin and Ventura basins, California; Uinta basin, Utah; and Piceance basin, Colorado. As of December 31, 2019, it had a total of 3,541 net producing wells. The company was formerly known as Berry Petroleum Corporation and changed its name to Berry Corporation in February 2020. Berry Corporation was founded in 1909 and is headquartered in Dallas, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Benefit Street Partners LLCDirectorSep 15Buy3.6788,452324,44212,703,275Sep 16 04:00 PM
Benefit Street Partners LLCDirectorSep 10Buy3.82300,0001,146,18012,614,823Sep 11 04:05 PM
Benefit Street Partners LLCDirectorSep 09Buy3.96175,000693,03512,314,823Sep 11 04:05 PM
Benefit Street Partners LLCDirectorSep 04Buy4.0031,000123,87312,139,823Sep 11 04:05 PM
Benefit Street Partners LLCDirectorSep 03Buy3.70110,000406,59312,108,823Sep 04 04:05 PM
Benefit Street Partners LLCDirectorSep 02Buy3.59155,000556,79111,998,823Sep 03 04:05 PM
Voiland EugeneDirectorMay 15Option Exercise0.0013,514043,514May 19 05:50 PM
PAUL DONALD LDirectorMay 15Option Exercise0.0013,514013,514May 19 05:49 PM
Potter Clifford KentDirectorMay 15Option Exercise0.0013,514019,883May 19 05:48 PM
MARIUCCI ANNE LDirectorMay 15Option Exercise0.0013,514033,286May 19 05:46 PM
Smith Arthur T.President & CEOMar 01Option Exercise0.00110,5880329,154Mar 03 09:39 PM
Baetz Cary DEVP & Chief Financial OfficerMar 01Option Exercise0.0020,9150206,490Mar 03 09:39 PM
Grove Gary AEVP & Chief Operating OfficerMar 01Option Exercise0.0018,8230170,185Mar 03 09:39 PM
Helm Michael S.Chief Accounting OfficerMar 01Option Exercise0.003,922016,859Mar 03 09:38 PM
Helm Michael S.Chief Accounting OfficerJan 16Option Exercise0.005,000014,496Jan 17 09:31 PM
Benefit Street Partners LLCDirectorDec 20Sale9.1516,830153,99511,843,823Dec 23 07:31 PM
Benefit Street Partners LLCDirectorDec 12Sale8.69534,9594,650,3990Dec 13 01:10 PM
Benefit Street Partners LLCDirectorDec 11Sale8.47365,0413,093,138534,959Dec 13 01:10 PM
Voiland EugeneDirectorNov 27Buy7.5716,600125,64716,600Nov 29 01:56 PM
MARIUCCI ANNE LDirectorNov 27Buy7.4713,403100,09419,772Nov 27 03:35 PM
Baetz Cary DEVP & Chief Financial OfficerNov 22Buy6.9514,00097,297185,575Nov 22 07:21 PM
Grove Gary AEVP & Chief Operating OfficerNov 22Buy7.0512,00084,577151,362Nov 22 07:21 PM
Smith Arthur T.President & CEONov 22Buy7.1515,000107,250218,566Nov 22 07:14 PM
Benefit Street Partners LLCDirectorNov 14Sale11.301,100,00012,430,000900,000Nov 18 04:56 PM
BSQR BSQUARE Corporation daily Stock Chart
BSQR [NASD]
BSQUARE Corporation
Index- P/E- EPS (ttm)-0.31 Insider Own5.90% Shs Outstand13.11M Perf Week3.54%
Market Cap16.70M Forward P/E- EPS next Y- Insider Trans27.65% Shs Float12.25M Perf Month-3.30%
Income-4.00M PEG- EPS next Q- Inst Own29.50% Short Float0.06% Perf Quarter-4.01%
Sales55.70M P/S0.30 EPS this Y34.10% Inst Trans3.05% Short Ratio0.21 Perf Half Y32.81%
Book/sh0.64 P/B2.05 EPS next Y- ROA-17.40% Target Price1.47 Perf Year19.27%
Cash/sh- P/C- EPS next 5Y- ROE-41.80% 52W Range0.83 - 2.00 Perf YTD-5.40%
Dividend- P/FCF- EPS past 5Y-41.00% ROI-96.20% 52W High-34.25% Beta1.44
Dividend %- Quick Ratio1.80 Sales past 5Y-9.20% Gross Margin16.00% 52W Low58.43% ATR0.07
Employees75 Current Ratio1.80 Sales Q/Q-37.30% Oper. Margin-7.30% RSI (14)47.08 Volatility5.16% 4.99%
OptionableYes Debt/Eq0.19 EPS Q/Q72.80% Profit Margin-7.20% Rel Volume0.28 Prev Close1.27
ShortableYes LT Debt/Eq0.11 EarningsAug 13 AMC Payout- Avg Volume32.28K Price1.32
Recom- SMA20-1.96% SMA50-4.90% SMA200-1.94% Volume8,882 Change3.54%
Oct-25-20 08:57AM  
Aug-13-20 04:05PM  
Jul-30-20 04:05PM  
Jun-16-20 09:04AM  
May-11-20 04:05PM  
Apr-28-20 06:52AM  
Apr-27-20 04:05PM  
Apr-22-20 04:05PM